Sugi Predict

Sugi Predict / Compounds / SCHEMBL4041024

SCHEMBL4041024

SCHEMBL4041024

CC(C)c1n[nH]c(C(=O)O)c1[N+](=O)[O-]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.36
▸ ALDH1A1 P00352 5/20 0.36
▸ CASP7 P55210 1/20 0.36
▸ CASP6 P55212 1/20 0.36
▸ HCAR3 P49019 1/20 0.34
▸ HCAR2 Q8TDS4 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34
▸ SENP6 Q9GZR1 1/20 0.34
▸ KMT2A Q03164 3/20 0.33
▸ GAA P10253 2/20 0.33
▸ FBP1 P09467 3/20 0.32
▸ MEN1 O00255 2/20 0.31
▸ PKM P14618 2/20 0.31
▸ POLB P06746 1/20 0.31
▸ NPY1R P25929 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043569 0.85 KDM4E (0.34) MAPTALDH1A1CASP7CASP6SMN1; SMN2
SCHEMBL5416942 0.79 MAPT (0.38) MAPTALDH1A1SMN1; SMN2NPC1KMT2A
SCHEMBL11340041 0.77 MAPT (0.42) MAPTALDH1A1CASP7CASP6NPC1
SCHEMBL16833007 0.75 MAPT (0.50) MAPTALDH1A1CASP7CASP6SMN1; SMN2
SCHEMBL21625525 0.75 MAPT (0.37) MAPTALDH1A1CASP7CASP6SMN1; SMN2
SCHEMBL331274 0.75 ALDH1A1 (0.36) MAPTALDH1A1CASP7CASP6HCAR2
SCHEMBL6446634 0.73 PKM (0.38) MAPTALDH1A1CASP7CASP6KMT2A
SCHEMBL3575824 0.73 ALDH1A1 (0.39) MAPTALDH1A1CASP7CASP6HCAR2
SCHEMBL17224859 0.72 HCAR2 (0.40) HCAR3HCAR2POLB
SCHEMBL17224870 0.72 HCAR2 (0.40) HCAR3HCAR2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
CN-110831600-B Indole AHR inhibitors and uses thereof 医肯纳肿瘤学公司 2023-10-17 — — CN disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
CN-110831600-A Indole AHR inhibitors and uses thereof 金恩医疗公司 2020-02-21 — — CN disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed
EP-1620437-B1 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION PFIZER LTD (GB) 2009-06-17 — — EP disclosed
CN-100439371-C 5, 7-diaminopyrazolo [4, 3-d ] pyrimidines useful in the treatment of hypertension PFIZER LTD (GB) 2008-12-03 — — CN disclosed
US-20070270412-A1 NOVEL PHARMACEUTICALS PFIZER INC 2007-11-22 — — US disclosed
US-7262192-B2 Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors PFIZER INC. (US) 2007-08-28 — — US disclosed
EP-1809632-A2 PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES USEFUL AS PDE-5 INHIBITORS Pharmacia & Upjohn Company LLC (US) 2007-07-25 — — EP disclosed
CN-1780841-A 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the traetment of hypertension PFIZER LTD (GB) 2006-05-31 — — CN disclosed
WO-2006046135-A2 PYRAZOLO[4,3-D] PYRIMIDINE DERIVATIVES USEFUL AS PDE-5 INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-05-04 — — WO disclosed
US-20050043325-A1 Novel pharmaceuticals PFIZER INC 2005-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 MAPT 4171/4885ALDH1A1 316/4885CASP7 3337/4885
US-20050043325-A1 Novel pharmaceuticals ABCB11, PCSK9, SLC10A1 MAPT 1823/4885ALDH1A1 851/4885CASP7 3473/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 MAPT 4171/4885ALDH1A1 316/4885CASP7 3337/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 MAPT 4171/4885ALDH1A1 316/4885CASP7 3337/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 MAPT 4171/4885ALDH1A1 316/4885CASP7 3337/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 MAPT 4171/4885ALDH1A1 316/4885CASP7 3337/4885
US-20070270412-A1 NOVEL PHARMACEUTICALS ABCB11, PCSK9, SLC10A1 MAPT 1823/4885ALDH1A1 851/4885CASP7 3473/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 MAPT 4171/4885ALDH1A1 316/4885CASP7 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.